Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

5 Jan 2010 09:00

RNS Number : 0210F
ViaLogy PLC
05 January 2010
 

VIALOGY PLC ("VIALOGY" OR "THE COMPANY")

JANUARY BUSINESS UPDATE

Signs QuantumRD contract with one of US's largest independents

Multiple wells scheduled for Q1

Milestone achieved on University of Texas collaboration site

LondonJanuary 5, 2010ViaLogy (LSE:VIY) ViaLogy announces it is under contract to provide its QuantumRD hydrocarbon reservoir discovery and characterization services to one of the largest privately held Independent Exploration & Production companies in America. Headquartered in Oklahoma, the firm operates internationally and across the United States both onshore and offshore. It currently controls over 4,000 wells. The contract represents an important opportunity for ViaLogy to expand the scope of its QuantumRD technology into new formations. The initial collaboration is focused on discovery and characterization of Pennsylvanian Morrow Sandstone at the Mescalero Springs prospect in Chaves CountyNew Mexico. ViaLogy will analyze 3-D seismic data to discover oil and gas stratigraphic targets with porosity to position wells between 11,000 ft and 12,000 ft depths, and deliver its recommendations in four weeks. The project will further validate QuantumRD's ability to resolve stratigraphic prospects below seismic resolution presently achievable by conventional processing. At the client's request, neither the firm's name nor details of the signed contract will be made public. 

ViaLogy also announces the signing of a contract for QuantumRD with Nordan Oil & Gas Corporation of AbileneTexas, that foresees multiple QuantumRD analysis projects.

These and other new contracts bring ViaLogy's current client base to eight, and its contingent order book of wells to more than 50 (based on the approximate number of drill locations the company expects to provide to clients under signed contracts to date). The company also reports a strong sales pipeline of prospective clients which should extend the use of QuantumRD to an increasing variety of geographical locations and geophysical formations.

The first quarter of 2010 is scheduled to see multiple wells drilled at locations already determined by ViaLogy's QuantumRD analysis. Once the company's recommendations are made, the dates and pace of drilling are decided solely by ViaLogy's clients and depend upon the clients' operational priorities, and such matters as permits, equipment availability, and even weather. In this connection, Atascosa Exploration's planned Escondido well, initially expected at the end of last year, has been delayed until this month due to unexpected lease issues. During the first quarter of this year the two successful wells already identified for Atascosa by ViaLogy will undergo rework to accelerate their production. Their estimates of recoverable barrels of oil remain unchanged. 

ViaLogy's collaboration with another large Texas independent oil and gas exploration company in conjunction with the University of Texas' Bureau of Economic Geology, announced in a July 2009 press release, has concluded an important milestone. Despite previous expert analysis, the chosen site had produced a number of 'dry holes'. ViaLogy's application of QuantumRD to existing data sets has determined new drill location recommendations, and drilling on this challenging 11,000 ft well is slated for the coming weeks. 

ViaLogy's work for Vecta Oil & Gas, announced in September, 2009 and also with the involvement of the Bureau of Economic Geology, has concluded its first phase with the delivery of ViaLogy's QuantumRD analysis and recommended multiple drilling locations. A number of these wells are scheduled for drilling in 2010.

Commenting on the latest New Mexico contract, ViaLogy CEO Robert W. Dean, said, "We are pleased and proud to be working for a company of this firm's stature and experience. They are at the forefront of the industry in applying the most advanced analytical tools, and our hope is to become a mainstay of support in their drilling efforts." On the larger picture regarding QuantumRD, Dean goes on to say "ViaLogy now has a full workload and looks forward to significant business breakthroughs in the coming months, always bearing in mind that we cannot be successful 100 percent of the time."

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756) 

Nominated Advisor to ViaLogy PLC (Seymour Pierce)

Mark Percy +44 (0) 20-7107-8000

About ViaLogy: Network Centric Signal Processing

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGUMAGUPUURA
Date   Source Headline
5th Nov 20207:00 amRNSDirectorate Change
3rd Nov 20207:00 amRNSPartnership with Take2 Health Limited
26th Oct 20207:00 amRNSHalf-year Trading update
23rd Oct 20207:00 amRNSCQC accreditation
21st Oct 20207:00 amRNSYourgene Genomic Services collaboration with Cytox
12th Oct 20207:00 amRNSElucigene DPYD tests to be used routinely in Wales
8th Oct 20207:00 amRNSStrategic reproductive health partnership in Japan
7th Oct 20207:00 amRNSIONA®Nx awarded contract with St George’s Hospital
5th Oct 20207:00 amRNSShare Incentive Plan
1st Oct 20204:59 pmRNSCorrection: Holding(s) in Company
1st Oct 20203:29 pmRNSHolding(s) in Company
28th Sep 20207:00 amRNSLaunch of Yourgene Genomic Services
25th Sep 20205:28 pmRNSIssue of Share Options
24th Sep 202010:00 amRNSDPD reimbursement in Germany
24th Sep 20207:00 amRNSDirector/PDMR Shareholding
23rd Sep 20205:20 pmRNSExercise of Options
23rd Sep 202012:25 pmRNSDirector/PDMR Shareholding
22nd Sep 20205:14 pmRNSResult of AGM
22nd Sep 20207:00 amRNSAGM Statement
21st Sep 20207:00 amRNSUS distribution agreement for DPYD &other products
9th Sep 20207:00 amRNSAGM update and investor presentation
3rd Sep 20207:00 amRNSIONA® Nx Launch
28th Aug 20207:00 amRNSNotice of AGM & Annual Report 2020
13th Aug 20207:00 amRNSTGA approves IONA® Nx for sale in Australia
11th Aug 20207:00 amRNSAdmission of Company Considerations Shares and TVR
7th Aug 20203:42 pmRNSHolding(s) in Company
7th Aug 20203:25 pmRNSHolding(s) in Company
7th Aug 20209:48 amRNSHolding(s) in Company
5th Aug 20201:15 pmRNSResult of Placing
5th Aug 20207:00 amRNS£16.15m Placing & Close of Accelerated Bookbuild
4th Aug 20205:13 pmRNSProposed Acquisition and Placing
3rd Aug 20207:00 amRNSCE-IVD Mark for Clarigene™ SARS-CoV-2 test
29th Jul 202012:05 pmRNSAppointment of Joint Broker
28th Jul 20207:00 amRNSFinal Results
13th Jul 20201:13 pmRNSNotice of Results
30th Jun 20207:00 amRNSCOVID-19 assay launched
19th Jun 20204:44 pmRNSIssue of Share Options
16th Jun 20207:00 amRNSCollaboration in COVID-19 testing
15th Jun 20207:00 amRNSCE-IVD mark received for Illumina-based IONA® test
26th May 202012:00 pmRNSHolding(s) in Company
26th May 20207:00 amRNSCOVID-19 testing service launch; business update
20th May 20207:00 amRNSExercise of Warrants and Options
20th Apr 20207:00 amRNSYear-end Trading update: Revenues increase 86%
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:36 pmRNSPrice Monitoring Extension
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:01 pmRNSPrice Monitoring Extension
7th Apr 20207:00 amRNSPresentation on ‘Adapting during crisis’

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.